<DOC>
	<DOCNO>NCT00732290</DOCNO>
	<brief_summary>Clopidogrel platelet aggregation inhibitor witch prevents thrombotic event patient atherosclerotic vascular disease . To date , 4 30 % patient consider poor , low non-responder therapeutic . However , drug-drug interaction may lead decrease clopidogrel responsiveness . Many argument support drug-drug interaction clopidogrel fluoxetine ( selective serotonin reuptake inhibitor ) . On pharmacokinetic level , fluoxetine inhibits cytochroms involve production clopidogrel active metabolite . On pharmacodynamic level fluoxetine could increase risk hemorrhage inhibit serotonin platelet reuptake thus enhance antiplatelet effect clopidogrel . The purpose study investigate influence fluoxetine pharmacokinetic pharmacodynamic clopidogrel .</brief_summary>
	<brief_title>Investigation Drug-drug Interaction Between Clopidogrel Fluoxetine</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Signed informed consent Body mass : 60 85 Kg Platelet count : 180 350 G/L % platelet aggregation &gt; 70 % Subjects good health determine medical history , physical examination include vital sign , clinical laboratory test result include liver function , renal full blood count Subject history seizure disorder Subject know allergy fluoxetine clopidogrel Cigarette smoking Subject history hemorrhagic disease Peptic ulcer Psychiatric disorder Participation another clinical device trial within three previous month Subject currently take medication Subject currently take medication depression Subject history depression ( MADRS score &lt; 15 ) Hepatic insufficiency</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>Polymorphism , Genetic</keyword>
</DOC>